Lidocaine
Postherpetic Neuralgia
Seoul National University HospitalSmall moleculePhase 4 / ApprovedDormant
BBB
78/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 76/ 100
- Competitive Position
- 81/ 100
Competitive context
18 Active assets in the Postherpetic Neuralgia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin Neurodawn Pharmaceutical Co., Ltd. | Phase 4 | BBB |
Gabapentin University of Medicine and Pharmacy at Ho Chi Minh City | Phase 4 | BBB |
Capsaicin Astellas Pharma Europe Ltd. | Phase 4 | BBB |
(±)-Tramadol Astellas Pharma Inc | Phase 4 | BB |
Crisugabalin Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Lidocaine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →